Trial of Reducing Inpatient Antibiotic Durations in Children

Conditions

• Pneumonia
• Skin and Soft Tissue (SST) Infection
• Urinary Tract Infections (UTIs)

Eligibility Criteria

Sex

ALL

Age

60 Days - 17 Years

Healthy Volunteers

Not accepted

Interventions

• Study Drug Placebo — DRUG
  Placebo, medically nonactive drug

Study Details

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Key Dates

Start date

Feb 13, 2026

Status verified

Apr 2026

Primary completion

Aug 31, 2031

Completion

Aug 31, 2031

Study Design

Enrollment

1,200 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: 5-day duration treatment strategy
  Participants will use the antibiotic prescribed by thier hospital care team for the first 5 days of antibiotic therapy. They will change to study medication, a placebo, for days 6-10 of therapy.
• No Intervention: 10-day duration treatment strategy
  Participants will use the antibiotic prescribed by thier hospital care team for the first 5 days of antibiotic therapy. They will change to study medication, a continuation of that antibiotic, for days 6-10 of therapy.

Primary Outcome Measure

DOOR-RADAR composite outcome at day 15 [ Time Frame: Day 15 after antibiotic initiation ]

Locations (10)

Find similar trials in Birmingham, AL

Related Studies

• Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
  Recruiting · Duke University · Phoenix, Arizona
• Adaptation and Pilot Implementation of ePNa Clinical Decision Support for Utah Urgent Care Clinics
  Recruiting · Intermountain Health Care, Inc. · American Fork, Utah
• Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
  PHASE2 · Recruiting · Vasomune Therapeutics, Inc. · Newport Beach, California
• A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
  Recruiting · Pfizer · El Centro, California